Impact of prior COVID‐19 infection on allogeneic hematopoietic stem cell transplantation outcomes.

There are limited data on outcomes of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in recipients with prior COVID‐19 infection. This single‐center retrospective study included 54 adult patients who received allo‐HSCT from July 2020 to September 2021 after previous COVID‐19 infection and 122 control group patients without a history of COVID‐19 who underwent HSCT during the same period, with a median follow‐up of 17 months. Median time from COVID‐19 to allo‐HSCT was 211 days. The incidence of main complications in the post‐transplant period was not significantly different between the two groups: deep vein thrombosis (p =.85), TMA (p =.8), VOD (p =.25), bloodstream infections (p =.21), pneumonia of any etiology (p =.41), viral infections (p =.85), invasive fungal disease (p =.08). The 2‐year non‐relapse mortality, relapse incidence, overall survival, and progression‐free survival also were comparable in the study and the control groups: 22% (95% CI 10.5–36.2) versus 26.3% (95% CI 18.7–34.6) p =.4; 15.6% (95% CI 7.3–26.9) versus 23.6% (95% CI 16.0–32.3) p =.39; 67.9% (95% CI 50.4–80.3) versus 59.8% (95% CI 50.2–68.1) p =.24 and 62.3% (95% CI 45.5–75.3) versus 49.9% (95% CI 40.0–59.1) p =.18, respectively. The history of previous COVID‐19 infection did not affect the results of allo‐HSCT. [ABSTRACT FROM AUTHOR]